Clinical Trial Update: BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

View source ↗

Summary

Completed clinical trial evaluating the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in cancer patients receiving active treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Pfizer-BioNTech COVID-19 Vaccine (tozinameran)

Snippet

Sponsor: Ente Ospedaliero Ospedali Galliera | Conditions: Neoplasms, Cancer, Treatment-Related | Status: COMPLETED